Genomics and new targets for multiple sclerosis

Pharmacogenomics

Volumn 6, Issue 2, 2005, Pages 151-161

  Baranzini, Sergio E ^a   Oksenberg, Jorge R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Genetics; Multiple sclerosis; Single nucleotide polymorphism

Indexed keywords

BETA INTERFERON; CYCLOPHOSPHAMIDE; DNA VACCINE; GLATIRAMER; GLUCOCORTICOID; INTERLEUKIN 14; MYELIN; NATALIZUMAB; RECOMBINANT BETA INTERFERON;

ALLELE; CLINICAL TRIAL; DISEASE COURSE; DISEASE MODEL; DISEASE PREDISPOSITION; DRUG MECHANISM; ENVIRONMENTAL FACTOR; FLU LIKE SYNDROME; FUNCTIONAL GENOMICS; GENE FUNCTION; GENETIC ANALYSIS; GENETIC DISORDER; GENETIC HETEROGENEITY; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; MENSTRUATION DISORDER; MULTIPLE SCLEROSIS; NONHUMAN; PATHOGENESIS; PREVALENCE; REVIEW; RISK FACTOR; SKIN MANIFESTATION; SPASTICITY; TRANSCRIPTION REGULATION; TREATMENT OUTCOME;

ANIMALS; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION TO DISEASE; GENOMICS; HUMANS; MULTIPLE SCLEROSIS;

EID: 18144368861     PISSN: 14622416     EISSN: None     Source Type: Journal    
DOI: 10.1517/14622416.6.2.151     Document Type: Review

References (49)

1. Hauser SL, Goodin DE: Multiple sclererosis and other demyelinating diseases. In: Harrison's Principle of International Medicine (15th edn). Braunwald E, Fauci AD, Kasper DL, Hauser SL, Longo DL, Jameson JL (Eds), McGraw Hill, NY (2004).
2. Oksenberg JR, Baranzini SE, Barcellos LF, Hauser SL: Multiple sclerosis: genomic rewards. J. Neuroimmunol. 113, 171-184 (2001).
3. Hohlfeld R, Wekerle H: Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines. Proc. Natl Acad. Sci. USA 101 (Suppl. 2), 14599-14606 (2004).
4. Compston A, Coles A: Multiple sclerosis. Lancet 359, 1221-1231 (2002).
5. Sadovnick AD: Familial recurrence risks and inheritance of multiple sclerosis. Curr. Opin. Neurol. Neurosurg. 6, 189-194 (1993).
6. Sadovnick AD, Ebers GC, Dyment DA, Risch NJ: Evidence for genetic basis of multiple sclerosis. Lancet 347, 1728-1730 (1996).
7. Ebers GC, Sadovnick AD, Risch NJ: A genetic basis for familial aggregation in multiple sclerosis. Nature 377, 150-151 (1995).
8. Mumford CJ, Wood NW, Kellar-Wood H et al.: The British Isles survey of multiple sclerosis in twins. Neurology 44, 11-15 (1994).
9. Brassat D, Azais-Vuillemin C, Yaouanq J et al.: Familial factors influence disability in MS multiplex families. French Multiple Sclerosis. Genetics Group. Neurology 52, 1632-1636 (1999).
10. Barcellos LF, Oksenberg JR, Green AJ et al.: Genetic basis for clinical expression in multiple sclerosis. Brain 125, 150-158 (2002).
11. Kantarci OH, de Andrade M, Weinshenker BG: Identifying disease modifying genes in multiple sclerosis. J. Neuroimmunol. 123, 144-159 (2002).
12. Ebers GC, Kukay K, Bulman DE et al.: A full genome search in multiple sclerosis. Nat. Genet. 13, 472-476 (1996).
13. Haines JL, Ter-Minassian M, Bazyk A et al.: A complete genomic screen for multiple sclerosis underscores a role for the major histocompatibility complex. Nat. Genet. 13, 469-471 (1996).
14. Sawcer S, Jones HB, Feakes R et al.: A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22. Nat. Genet. 13, 464-468 (1996).
15. The Transatlantic Multiple Sclerosis Cooperative: A meta-analysis of genomic screens in multiple sclerosis. Mult. Scler. 7, 3-11 (2001).
16. GAMES, Transatlantic Multiple Sclerosis Genetics Cooperative: A meta-analysis of whole genome linkage screens in multiple sclerosis. J. Neuroimmunol. 143, 39-46 (2003).
17. Barcellos LF, Oksenberg JR, Begovich AB et al.: HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course. Am. J. Hum. Genet. 72, 710-716 (2003).
18. Fusco C, Andreone V, Coppola G et al.: HLA-DRB1*1501 and response to copolymer-1 therapy in relapsing-remitting multiple sclerosis. Neurology 57, 1976-1979 (2001).
19. Haines JL, Terwedow HA, Burgess K et al.: Linkage of the MHC to familial multiple sclerosis suggests genetic heterogeneity. Hum. Mol. Genet. 7, 1229-1234 (1998).
20. Wise LH, Lanchbury JS, Lewis CM: Meta-analysis of genome searches. Ann. Hum. Genet. 63, 263-272 (1999).
21. Gabriel SB, Schaffner SF, Nguyen H et al.: The structure of haplotype blocks in the human genome. Science 296, 2225-2229 (2002).
22. Horikawa Y, Oda N, Cox NJ et al.: Genetic variation in the gene encoding calpain-10 is associated with Type 2 diabetes mellitus. Nat. Genet. 26, 163-175 (2000).
23. Ogura Y, Bonen DK, Inohara N et al.: A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411, 603-606 (2001).
24. Rioux JD, Daly MJ, Silverberg MS et al.: Genetic variation in the 5q31 cytokine gene cluster confers susceptibility to Crohn disease. Nat. Genet. 29, 223-228 (2001).
25. Van Eerdewegh P, Little RD, Dupuis J et al.: Association of the ADAM33 gene with asthma and bronchial hyperresponsiveness. Nature 418, 426-430 (2002).
26. Laitinen T, Polvi A, Rydman P et al.: Characterization of a common susceptibility locus for asthma-related traits. Science 304, 300-304 (2004).
27. Stefansson H, Sigurdsson E, Steinthorsdottir V et al.: Neuregulin 1 and susceptibility to schizophrenia. Am. J. Hum. Genet. 71, 877-892 (2002).
28. Einarsdottir E, Soderstrom I, Lofgren-Burstrom A et al.: The CTLA4 region as a general autoimmunity factor: an extended pedigree provides evidence for synergy with the HLA locus in the etiology of Type 1 diabetes mellitus, Hashimoto's thyroiditis and Graves' disease. Eur. J. Hum. Genet. 11, 81-84 (2003).
29. Becker KG, Mattson DH, Powers JM, Gado AM, Biddison WE: Analysis of a sequenced cDNA library from multiple sclerosis lesions. J. Neuroimmunol. 77, 27-38 (1997).
30. Whitney LW, Becker KG, Tresser NJ et al.: Analysis of gene expression in mutiple sclerosis lesions using cDNA microarrays. Ann. Neurol. 46, 425-428 (1999).
31. Chabas D, Baranzini SE, Mitchell D et al.: The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 294, 1731-1735 (2001).
32. van Noort JM, van Sechel AC, Bajramovic JJ et al.: The small heat-shock protein α B-crystallin as candidate autoantigen in multiple sclerosis. Nature 375, 798-801 (1995).
33. Lock C, Hermans G, Pedotti R et al.: Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat. Med. 8, 500-508 (2002).
34. Graumann U, Reynolds R, Steck AJ, Schaeren-Werners N: Molecular changes in normal appearing white matter in multiple sclerosis are characteristic of neuroprotective mechanisms against hypoxic insult. Brain Pathol. 13, 554-573 (2003).
35. Lindberg RL, De Groot CJ, Certa U et al.: Multiple sclerosis as a generalized CNS disease. Comparative microarray analysis of normal appearing white matter and lesions in secondary progressive MS. J. Neuroimmunol. 152, 154-167 (2004).
36. Baranzini SE, Hauser SL: Large-scale gene-expression studies and the challenge of multiple sclerosis. Genome Biol. 3, 1027 (2002).
37. Bomprezzi R, Ringner M, Kim S et al.: Gene expression profile in multiple sclerosis patients and healthy controls: identifying pathways relevant to disease. Hum. Mol. Genet. 12, 2191-2199 (2003).
38. Achiron A, Gurevich M, Friedman N, Kaminski N, Mandel M: Blood transcriptional signatures of multiple sclerosis: unique gene expression of disease activity. Ann. Neurol. 55, 410-417 (2004).
39. Marshall E: Getting the noise out of gene arrays. Science 306, 630-631 (2004).
40. Jacobs L, O'Malley J, Freeman A, Ekes R: Intrathecal interferon reduces exacerbations of multiple sclerosis. Science 214, 1026-1028 (1981).
41. Jacobs L, Salazar AM, Herndon R et al.: Multicentre double-blind study of effect of intrathecally administered natural human fibroblast interferon on exacerbations of multiple sclerosis. Lancet 2, 1411-1413 (1986).
42. Polman CH, Herndon RM, Pozzilli C: Interferons. In: Multiple Sclerosis Therapeutics. Rudick RA, Goodkin DE (Eds), Martin Dunitz, London 243-276 (1999).
43. Rio J, Nos C, Tintore M et al.: Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon beta: implications for clinical trials. Ann. Neurol. 52, 400-406 (2002).
44. Wiendl H, Hohlfeld R: Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials. BioDrugs 16, 183-200 (2002).
45. Villoslada P, Barcellos L, Rio J et al.: The HLA locus and multiple sclerosis in Spain. Role in disease susceptibility, clinical course and response to interferon-β. J. Neuroimmunol. 130, 194-201 (2002).
46. Sriram U, Barcellos LF, Villoslada P et al.: Pharmacogenomic analysis of interferon receptor polymorphisms in multiple sclerosis. Genes Immun. 4, 147-152 (2003).
47. Hong J, Zang YC, Hutton G, Rivera VM, Zhang JZ: Gene expression profiling of relevant biomarkers for treatment evaluation in multiple sclerosis. J. Neuroimmunol. 152, 126-139 (2004).
48. Weinstock-Guttman B, Badgett D, Patrick K et al.: Genomic effect of IFN-β in multiple sclerosis patients. J. Immunol. 171, 2694-2702 (2003).
49. Baranzini SE, Mousav P, Rio J et al.: Transcription-based prediction of response to IFNβ using supervised computational methods. PLOS Biol. 3e2, 1-11 (2005).